Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04746924




Registration number
NCT04746924
Ethics application status
Date submitted
5/02/2021
Date registered
10/02/2021
Date last updated
26/10/2024

Titles & IDs
Public title
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Scientific title
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
BGB-A317-A1217-302
Secondary ID [2] 0 0
AdvanTIG-302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
NSCLC 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tislelizumab
Treatment: Drugs - Ociperlimab
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Placebo

Experimental: Arm A: Tislelizumab plus Ociperlimab - Participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks.

Active comparator: Arm B: Pembrolizumab plus Placebo - Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.

Placebo comparator: Arm C: Tislelizumab plus Placebo - Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.


Treatment: Drugs: Tislelizumab
Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Treatment: Drugs: Ociperlimab
Ociperlimab is a monoclonal antibody formulated for intravenous injection.

Treatment: Drugs: Pembrolizumab
Pembrolizumab is a monoclonal antibody formulated for intravenous injection.

Treatment: Drugs: Placebo
Placebo infusions will consist of a sterile, normal saline solution.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 58 months
Secondary outcome [1] 0 0
Progression-free Survival (PFS) As Assessed By Investigators
Timepoint [1] 0 0
Up to approximately 58 months
Secondary outcome [2] 0 0
Overall Response Rate (ORR) As Assessed By Investigators
Timepoint [2] 0 0
Up to approximately 58 months
Secondary outcome [3] 0 0
Duration Of Response (DOR) As Assessed By Investigators
Timepoint [3] 0 0
Up to approximately 58 months
Secondary outcome [4] 0 0
Health-related Quality Of Life (HRQoL): European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30)
Timepoint [4] 0 0
Within 7 days after permanent treatment discontinuation
Secondary outcome [5] 0 0
HRQoL: EORTC Lung Cancer Module Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) HRQoL will be assessed via PRO using the EORTC QLQ-LC13.
Timepoint [5] 0 0
Within 7 days after permanent treatment discontinuation
Secondary outcome [6] 0 0
HRQoL: European Quality of Life-5 Level- 5 Dimension (EQ-5D-5L) Questionnaire
Timepoint [6] 0 0
Within 7 days after permanent treatment discontinuation
Secondary outcome [7] 0 0
Time To Deterioration (TTD)
Timepoint [7] 0 0
Within 7 days after permanent treatment discontinuation
Secondary outcome [8] 0 0
Number Of Participants Experiencing Adverse Events (AEs)
Timepoint [8] 0 0
90 days (±14) after last dose

Eligibility
Key inclusion criteria
Key

1. Histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous NSCLC.
2. No prior systemic treatment for metastatic NSCLC.
3. Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).
4. Tumors with PD-L1 expressed in = 50% tumor cells.
5. At least 1 measurable lesion as defined per RECIST v1.1.
6. ECOG Performance Status = 1.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
4. Active autoimmune diseases or history of autoimmune diseases that may relapse.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
7/02/2027
Actual
Sample size
Target
Accrual to date
Final
662
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Pindara Private Hospital - Benowa
Recruitment hospital [2] 0 0
Mater Cancer Care Centre - South Brisbane
Recruitment hospital [3] 0 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [4] 0 0
Ballarat Health Services - Ballarat
Recruitment hospital [5] 0 0
Monash Health - Clayton
Recruitment hospital [6] 0 0
Western Health Sunshine Hospital - St Albans
Recruitment hospital [7] 0 0
St John of God, Murdoch - Murdoch
Recruitment postcode(s) [1] 0 0
4217 - Benowa
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [4] 0 0
3350 - Ballarat
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3021 - St Albans
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
Argentina
State/province [8] 0 0
Tucuman
Country [9] 0 0
Brazil
State/province [9] 0 0
Brasilia
Country [10] 0 0
Brazil
State/province [10] 0 0
Cachoeiro de Itapemirim
Country [11] 0 0
Brazil
State/province [11] 0 0
Florianopolis
Country [12] 0 0
Brazil
State/province [12] 0 0
Sao Jose do Rio Preto
Country [13] 0 0
China
State/province [13] 0 0
Anhui
Country [14] 0 0
China
State/province [14] 0 0
Beijing
Country [15] 0 0
China
State/province [15] 0 0
Chongqing
Country [16] 0 0
China
State/province [16] 0 0
Fujian
Country [17] 0 0
China
State/province [17] 0 0
Guangdong
Country [18] 0 0
China
State/province [18] 0 0
Guangxi
Country [19] 0 0
China
State/province [19] 0 0
Heilongjiang
Country [20] 0 0
China
State/province [20] 0 0
Henan
Country [21] 0 0
China
State/province [21] 0 0
Hubei
Country [22] 0 0
China
State/province [22] 0 0
Hunan
Country [23] 0 0
China
State/province [23] 0 0
Jiangsu
Country [24] 0 0
China
State/province [24] 0 0
Liaoning
Country [25] 0 0
China
State/province [25] 0 0
Shaanxi
Country [26] 0 0
China
State/province [26] 0 0
Shandong
Country [27] 0 0
China
State/province [27] 0 0
Shanghai
Country [28] 0 0
China
State/province [28] 0 0
Shanxi
Country [29] 0 0
China
State/province [29] 0 0
Sichuan
Country [30] 0 0
China
State/province [30] 0 0
Tianjin
Country [31] 0 0
China
State/province [31] 0 0
Xinjiang
Country [32] 0 0
China
State/province [32] 0 0
Zhejiang
Country [33] 0 0
France
State/province [33] 0 0
Bayonne
Country [34] 0 0
France
State/province [34] 0 0
Bordeaux
Country [35] 0 0
France
State/province [35] 0 0
Lyon
Country [36] 0 0
France
State/province [36] 0 0
Montpellier
Country [37] 0 0
France
State/province [37] 0 0
Nancy
Country [38] 0 0
France
State/province [38] 0 0
Paris cedex
Country [39] 0 0
France
State/province [39] 0 0
saint Mande
Country [40] 0 0
France
State/province [40] 0 0
Saint Pierre
Country [41] 0 0
France
State/province [41] 0 0
SaintHerblain
Country [42] 0 0
France
State/province [42] 0 0
Tours
Country [43] 0 0
Georgia
State/province [43] 0 0
Batumi
Country [44] 0 0
Georgia
State/province [44] 0 0
Tbilisi
Country [45] 0 0
Germany
State/province [45] 0 0
Aachen
Country [46] 0 0
Germany
State/province [46] 0 0
Bonn
Country [47] 0 0
Germany
State/province [47] 0 0
Giessen
Country [48] 0 0
Germany
State/province [48] 0 0
Grobhansdorf
Country [49] 0 0
Germany
State/province [49] 0 0
Hamburg
Country [50] 0 0
Germany
State/province [50] 0 0
Koln
Country [51] 0 0
Germany
State/province [51] 0 0
Munich
Country [52] 0 0
Germany
State/province [52] 0 0
Rotenburg
Country [53] 0 0
Italy
State/province [53] 0 0
Bologna
Country [54] 0 0
Italy
State/province [54] 0 0
Messina
Country [55] 0 0
Italy
State/province [55] 0 0
Orbassano
Country [56] 0 0
Japan
State/province [56] 0 0
Aichi
Country [57] 0 0
Japan
State/province [57] 0 0
Aomori
Country [58] 0 0
Japan
State/province [58] 0 0
Ehime
Country [59] 0 0
Japan
State/province [59] 0 0
Fukuoka
Country [60] 0 0
Japan
State/province [60] 0 0
Gunma
Country [61] 0 0
Japan
State/province [61] 0 0
Hyogo
Country [62] 0 0
Japan
State/province [62] 0 0
Ishikawa
Country [63] 0 0
Japan
State/province [63] 0 0
Kanagawa
Country [64] 0 0
Japan
State/province [64] 0 0
Miyagi
Country [65] 0 0
Japan
State/province [65] 0 0
Okayama
Country [66] 0 0
Japan
State/province [66] 0 0
Osaka
Country [67] 0 0
Japan
State/province [67] 0 0
Tochigi
Country [68] 0 0
Japan
State/province [68] 0 0
Tokyo
Country [69] 0 0
Japan
State/province [69] 0 0
Hiroshima
Country [70] 0 0
Japan
State/province [70] 0 0
Niigata
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Chungcheongbukdo
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Daegu Gwang'yeogsi
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Gyeonggi-do
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Gyeongsangbukdo
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Seoul Teugbyeolsi
Country [76] 0 0
Mexico
State/province [76] 0 0
Monterrey
Country [77] 0 0
Netherlands
State/province [77] 0 0
Harderwijk
Country [78] 0 0
Netherlands
State/province [78] 0 0
Heerlen
Country [79] 0 0
Netherlands
State/province [79] 0 0
Zwolle
Country [80] 0 0
Poland
State/province [80] 0 0
Bialystok
Country [81] 0 0
Poland
State/province [81] 0 0
Lodz
Country [82] 0 0
Poland
State/province [82] 0 0
Poznan
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Moskva
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Nizhegorodskaya Oblast'
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Omskaya Oblast'
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Sankt-Peterburg
Country [87] 0 0
Spain
State/province [87] 0 0
Alcorcon
Country [88] 0 0
Spain
State/province [88] 0 0
Barcelona
Country [89] 0 0
Spain
State/province [89] 0 0
Elche
Country [90] 0 0
Spain
State/province [90] 0 0
Girona
Country [91] 0 0
Spain
State/province [91] 0 0
Jaen
Country [92] 0 0
Spain
State/province [92] 0 0
Las Palmas
Country [93] 0 0
Spain
State/province [93] 0 0
Lugo
Country [94] 0 0
Spain
State/province [94] 0 0
Madrid
Country [95] 0 0
Spain
State/province [95] 0 0
Majadahonda
Country [96] 0 0
Spain
State/province [96] 0 0
Malaga
Country [97] 0 0
Spain
State/province [97] 0 0
Murcia
Country [98] 0 0
Spain
State/province [98] 0 0
Orense
Country [99] 0 0
Spain
State/province [99] 0 0
Palma de Mallorca
Country [100] 0 0
Spain
State/province [100] 0 0
Sevilla
Country [101] 0 0
Spain
State/province [101] 0 0
Valencia
Country [102] 0 0
Taiwan
State/province [102] 0 0
Changhua
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taichung
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taipei
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taoyuan
Country [106] 0 0
Taiwan
State/province [106] 0 0
Yunlin
Country [107] 0 0
Thailand
State/province [107] 0 0
Bangkok
Country [108] 0 0
Thailand
State/province [108] 0 0
Hat Yai
Country [109] 0 0
Thailand
State/province [109] 0 0
Lak Si
Country [110] 0 0
Thailand
State/province [110] 0 0
Muang
Country [111] 0 0
Thailand
State/province [111] 0 0
Ratchathewi
Country [112] 0 0
Turkey
State/province [112] 0 0
Adana
Country [113] 0 0
Turkey
State/province [113] 0 0
Ankara
Country [114] 0 0
Turkey
State/province [114] 0 0
Battalgazi
Country [115] 0 0
Turkey
State/province [115] 0 0
Edirne
Country [116] 0 0
Turkey
State/province [116] 0 0
Istanbul
Country [117] 0 0
Turkey
State/province [117] 0 0
Izmir
Country [118] 0 0
Turkey
State/province [118] 0 0
Kocaeli
Country [119] 0 0
Turkey
State/province [119] 0 0
Meram
Country [120] 0 0
Turkey
State/province [120] 0 0
Mersin City Hospital
Country [121] 0 0
Turkey
State/province [121] 0 0
Stanbul
Country [122] 0 0
Ukraine
State/province [122] 0 0
Kryvyi Rih
Country [123] 0 0
Ukraine
State/province [123] 0 0
Uzhgorod
Country [124] 0 0
Ukraine
State/province [124] 0 0
Uzhhorod

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Trial website
https://clinicaltrials.gov/study/NCT04746924
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Shun Lu
Address 0 0
Shanghai Chest Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BeiGene
Address 0 0
Country 0 0
Phone 0 0
1-877-828-5568
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04746924